疏风解毒胶囊治疗轻中度COVID-19:多中心随机双盲安慰剂对照II期试验
该多中心随机双盲安慰剂对照试验纳入407例轻中度COVID-19患者,评估疏风解毒胶囊疗效与安全性。结果显示,疏风解毒胶囊组所有症状缓解中位时间较安慰剂组缩短1天(7天 vs 8天,p=0.037),并显著改善发热/寒战和头痛,且安全性良好。
要点
- 疏风解毒胶囊可缩短轻中度COVID-19患者所有症状缓解时间1天。
- 疏风解毒胶囊显著改善发热/寒战和头痛,并加速体温恢复正常。
- 疏风解毒胶囊安全性良好,未报告严重不良事件。
核心结论
- 5天疏风解毒胶囊治疗可使轻中度COVID-19患者总体症状缓解时间缩短1天,尤其改善头痛和发热/寒战,且安全性良好。
研究设计与样本
- 筛查478例,最终407例完成试验并随机分配(疏风解毒胶囊组n=203,安慰剂组n=204)。
- 纳入发病3天内出现呼吸道症状的轻中度COVID-19患者,按1:1随机分组,每日三次口服疏风解毒胶囊或安慰剂,连续5天。
- 主要结局为从基线至随访结束的症状缓解时间。
主要发现
- 疏风解毒胶囊组所有症状缓解中位时间为7天,安慰剂组为8天(p=0.037)。
- 疏风解毒胶囊组发热/寒战缓解显著优于安慰剂组(p=0.04)。
- 疏风解毒胶囊组头痛缓解显著优于安慰剂组(p=0.016)。
- 疏风解毒胶囊组24小时内体温恢复正常的中位时间较安慰剂组缩短7小时(p=0.033)。
- 试验期间无死亡或严重/危重病例,未报告严重不良事件。
临床怎么用
- 对于发病3天内出现呼吸道症状的轻中度COVID-19患者,可考虑使用疏风解毒胶囊以缩短症状缓解时间。
- 疏风解毒胶囊可能对发热/寒战和头痛等症状有改善作用。
局限性
- 试验在独特的受控医院环境中进行,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: The COVID-19 pandemic has had a profound global impact, although the majority of recently infected cases have presented with mild to moderate symptoms. Previous clinical studies have demonstrated that Shufeng Jiedu (SFJD) capsule, a Chinese herbal patent medicine, effectively alleviates symptoms associated with the common cold, H1N1 influenza, and COVID-19. This study aimed to assess the efficacy and safety of SFJD capsules in managing symptoms of mild to moderate COVID-19 infection. Methods: A randomized, double-blind, placebo-controlled trial was conducted from May to December 2022 at two hospitals in China. Mild and moderate COVID-19-infected patients presenting respiratory symptoms within 3 days from onset were randomly assigned to either the SFJD or placebo groups in a 1:1 ratio. Individuals received SFJD capsules or a placebo three times daily for five consecutive days. Participants were followed up for more than 14 days after their RT-PCR nucleoid acid test for SARS-CoV-2 turned negative. The primary outcome measure was time to alleviate COVID-19 symptoms from baseline until the end of follow-up. Results: A total of 478 participants were screened; ultimately, 407 completed the trial after randomization (SFJD, n = 203; placebo, n = 204). No statistically significant difference in baseline parameters was observed between the two groups. The median time to alleviate all symptoms was 7 days in the SFJD group compared to 8 days in the placebo group (p = 0.037). Notably, the SFJD group significantly attenuated fever/chills (p = 0.04) and headache (p = 0.016) compared to the placebo group. Furthermore, the median time taken to reach normal body temperature within 24 h was reduced by 7 hours in the SFJD group compared to the placebo group (p = 0.033). No deaths or instances of serious or critical conditions occurred during this trial period; moreover, no serious adverse events were reported. Conclusion: The trial was conducted in a unique controlled hospital setting, and the 5-day treatment with SFJD capsules resulted in a 1-day reduction in overall symptoms, particularly headache and fever/chills, among COVID-19-infected participants with mild or moderate symptoms. Compared to placebo, SFJD capsules were found to be safe with fewer side effects. SFJD capsules could potentially serve as an effective treatment for alleviating mild to moderate symptoms of COVID-19. Clinical Trial Registration: https://www.isrctn.com/, identifier ISRCTN14236594.
引用
- Lu CL, Yang LQ, Jin XY, et al. Chinese herbal medicine Shufeng Jiedu capsule for mild to moderate COVID-19: a multicenter, randomized, double-blind, placebo-controlled phase II trial. Front Pharmacol. 2024. PMID: 38863976. doi:10.3389/fphar.2024.1383831
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。